CD19 and infectious disease: Given that CD19-directed CAR T-cells target normal B cells, adverse effects such as B-cell aplasia and hypogammaglobulinemia are anticipated subsequent to anti-CD19 or anti-CD22 CAR T-cell therapy, potentially predisposing individuals to various infectious diseases [135, 136].